Objectives
This study aimed to evaluate and compare the immunohistochemical expression of OCT-4
and SOX-2 and to determine their use in differentiating giant cell tumor (GCT) from
central giant cell granuloma (CGCG) and peripheral giant cell granuloma (PGCG).
Study Design
Formalin-fixed, paraffin-embedded tissue blocks of 10 histopathologically diagnosed
cases of GCT, CGCG, or PGCG were examined for anti–OCT-4 and anti–SOX-2 antibodies.
Nuclear staining of stromal mononuclear cells and multinucleated giant cells was considered
positive for OCT-4 and SOX-2 expression.
Results
Nuclear immunoexpression of OCT-4 in stromal mononuclear cells was observed in 80%
(8 of 10) of GCT cases, whereas none of the CGCG and PGCG cases showed OCT-4 immunoreactivity.
SOX-2 immunoreactivity was negative in GCT, CGCG, and PGCG.
Conclusions
OCT-4 immunopositivity in GCT can be used as a cancer stem cell marker to differentiate
GCT from CGCG and PGCG. The presence of OCT-4 in GCT versus its complete absence in
CGCG and PGCG suggests that these three conditions are separate entities. The absence
of stem cell marker OCT-4 and SOX-2 raises questions regarding their role in the pathogenesis
of CGCG and PGCG.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Computer assisted histomorphologic comparison and the expression of AgNORs in the central and peripheral giant cell lesions of the oral cavity and giant cell tumor of the long bone.J Oral Maxillofac Pathol. 2014; 18: 54-59
- Giant cell reparative granuloma, traumatic bone cyst and fibrous (fibro-osseous) dysplasia of jaw bones.Oral Surg Oral Med Oral Pathol. 1953; 6: 159-175
- Radiologic features, including those seen with computer tomography of central giant cell granulomas of the jaws..Oral Surg Oral Med Oral Pathol. 1988; 65: 255-261
- Histopathological and immunohistochemical study of giant cell granuloma of the jaw and giant cell tumour of long bones (comparative study).Iraqi Postgrad Med J. 2011; 10: 33-39
- Peripheral giant cell granuloma. Clinicopathologic study of 224 new cases.Int J Oral Maxillofac Surg. 1988; 17: 94-99
- Growth potential of peripheral giant cell granuloma.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 83: 548-551
- Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.Clin Orthop Surg. 2012; 4: 107-116
- The conservative treatment of giant cell sarcoma, with the study of bone transplantation.Ann Surg. 1912; 56: 210-239
- Giant cell tumor of bone revisited.SICOT J. 2017; 3: 54
- Giant cell tumor of bone.Am J Clin Oncol. 2006; 29: 96-99
- Central giant cell granuloma of the jaws: a clinical, radiologic, and histopathologic study of 26 cases.Oral Surg Oral Med Oral Pathol. 2006; 101: 346-354
- Evaluation of p53, PCNA, Ki‐67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.Oral Dis. 2000; 6: 35-39
- Central giant cell lesions of the jaws: a clinical, radiologic and histopathologic study.Oral Surg Oral Med Oral Pathol. 1993; 75: 199-208
- Stro‐1+ stromal cells have stem‐like features in giant cell tumor of bone.J Surg Oncol. 2012; 106: 826-836
- Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.Cancer Res. 2009; 69: 1302-1313
- High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.J Cell Mol Med. 2009; 13: 2236-2252
- Cancer stem cells and novel targets for antitumor strategies.Curr Pharmaceut Design. 2012; 18: 2838-2849
- The role of cancer stem cells in relapse of solid tumors.Front Biosci (Elite Ed). 2012; 4: 1528-1541
- POU domain family values: flexibility, partnerships, and developmental codes.Genes Dev. 1997; 11: 1207-1225
- The OCT 4 protein: more than a magic stemness marker.Am J Stem Cells. 2014; 3: 74-82
- Advances in reprogramming somatic cells to induced pluripotent stem cells.Stem Cell Rev. 2010; 6: 367-380
- An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.Nat Genet. 2008; 40: 499-507
- ALCAM+ stromal cells: role in giant cell tumor of bone progression.Cell Death Dis. 2018; 9: 299
- Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib.Cell Death Dis. 2014; 5: e1471
- Expression of embryonic stem cell markers in pyogenic granuloma.J Cutan Pathol. 2016; 43: 1096-1101
- Good clinical practice: historical background and key aspects.Nucl Med Commun. 2005; 26: 563-574
- Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.Cancer Res. 1990; 50: 7057-7061
- SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3 K/AKT/SOX2 axis and beyond.Oncogene. 2019; 2: 1-5
- Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis.Cancer Treat Rev. 2016; 51: 1-9
- A histological comparison of the giant cells in the central giant cell granuloma of the jaws and the giant cell tumour of long bone.J Oral Pathol. 1974; 3: 217-223
Article info
Publication history
Published online: May 31, 2020
Accepted:
March 31,
2020
Received in revised form:
February 25,
2020
Received:
November 14,
2019
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
